| Literature DB >> 31465774 |
Abstract
Aryl hydrocarbon receptor (AHR), identified in studies of dioxin toxicity, has been characterized as ligand-activated transcription factor involved in diverse functions including microbial defense, cell proliferation, immunity and NAD metabolism. AHR targets of the latter function are PARPs/ARTs and CD38 that are regulating glucose and lipid metabolism via NAD-dependent sirtuins. Deregulation of these pathways may facilitate obesity and age-dependent pathologies. The present commentary is focused on AHR and CD38 signaling in liver. CD38 is functioning as ectoNADase and Ca2+ mobilizing enzyme in endoplasmic reticulum and endolysosomal membranes. Deregulation of TCDD-activated AHR and CD38 may facilitate hepatic steatosis and inflammation. However, these proteins are also involved in protection against inflammation and CD38-mediated age-related decreased NAD levels that may be responsible for neurodegeneration. Further knowledge about the complexity of these pathways is needed to avoid pathologies. Therapeutic modulation of AHR and CD38 remains a challenging task.Entities:
Keywords: 2,3,7,8-Tetrachlorodibenzo-p-dioxin = TCDD (PubChem 15625); AHR, CD38, NAD metabolism; Hepatic steatosis; NASH; Nicotinamide (PubChem CID 936); Nicotinamide adenine dinucleotide = NAD (PubChem CID 5893); Nicotinamide riboside (PubChem CID 439924)
Year: 2019 PMID: 31465774 DOI: 10.1016/j.bcp.2019.08.022
Source DB: PubMed Journal: Biochem Pharmacol ISSN: 0006-2952 Impact factor: 5.858